Join

Compare · ANIP vs NVS

ANIP vs NVS

Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ANIP and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $284.62B, about 156.2x ANIP ($1.82B).
  • Over the past year, ANIP is up 28.9% and NVS is up 24.6% - ANIP leads by 4.2 points.
  • ANIP has hit the wire 2 times in the past 4 weeks while NVS has been quiet.
  • NVS has more recent analyst coverage (25 ratings vs 11 for ANIP).
PerformanceANIP+28.87%NVS+24.63%
2025-06-09+0.00%2026-06-08
MetricANIPNVS
Company
ANI Pharmaceuticals Inc.
Novartis AG
Price
$81.43+0.47%
$147.10-1.32%
Market cap
$1.82B
$284.62B
1M return
-3.15%
+1.13%
1Y return
+28.87%
+24.63%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
News (4w)
2
0
Recent ratings
11
25
ANIP

ANI Pharmaceuticals Inc.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest ANIP

Latest NVS